Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.
Frequently asked questions
What sector does Cybin Inc. Common Stock (HELP) operate in?
Cybin Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Cybin Inc. Common Stock (HELP) current stock price?
As of the latest data, Cybin Inc. Common Stock stock price is $10.36, with a previous close of $10.19. Cybin Inc. Common Stock gained $0.17 in the last trading session, representing a 1.67% increase.
What is Cybin Inc. Common Stock (HELP) current market capitalization?
Cybin Inc. Common Stock market cap is approximately 756.90 million.
What is Cybin Inc. Common Stock (HELP) Earnings Per Share (EPS)?
The trailing EPS is -$4.15, and the forward EPS is -$3.34.
What is Cybin Inc. Common Stock (HELP) EBITDA?
Cybin Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -47.81 million.
Does Cybin Inc. Common Stock (HELP) pay dividends?
No. Cybin Inc. Common Stock does not pay a dividend.
When is Cybin Inc. Common Stock (HELP) next earnings report?
Cybin Inc. Common Stock is expected to release its next earnings report on September 30, 2026.
What is Cybin Inc. Common Stock (HELP) beta (volatility) score?
Cybin Inc. Common Stock has a beta of 0.539, indicating lower volatility than the overall market.
